The Evaluation of Tolvaptan Therapy and Long-Term Prognosis in Hepatocellular Carcinoma with Refractory Ascites

• 作者: Daiki Tanaka Hiroaki Iwase Hisashi Kondo Masaaki Shimada Masashi Saito Noboru Hirashima Noboru Urata Satoshi Unita Takashi Kondo
• 来源期刊: 肠胃病学期刊(英文)
• 学科: 医学
• 关键词: TOLVAPTAN HEPATIC ASCITES SARCOPENIA LOOP DIURETICS Long-Term Prognosis
• 年，卷（期）: 2018,（2）
• 页码范围: 39-44
• 页数: 6页
• 分类号: R5

摘要

We investigated Tolvaptan efficacy and long-term prognosis with focus on nutrition in 20 patients with refractory hepatic ascites in hepatocellular carcinoma (HCC). Bloating improved in 55% of patients, as determined using a Japanese version of the Support Team Assessment Schedule. Nutritional status improved with Tolvaptan treatment, based on the Controlling Nutritional Status score and Onodera’s prognostic nutritional index. Long-term prognosis was better in responders than in non-responders (mean survival time: 308 days vs. 97 days, p = 0.031). Tolvaptan was even effective in many patients with HCC, with additional improvement in long-term prognosis expected with improvement in the nutritional status.